Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
NICHD: R&D: BPCA PEDIATRIC DRUG DEVELOPMENT CLINICAL TRIAL INFRASTRUCTURE: SEVERABLEDepartment of Health and Human Services$5.0M obligationsEnds Sep 19, 2027
POPULATION HEALTH RESEARCH SUPPORT - TASK ORDER A: START UP, PREPARATION, AND TEST ENROLLMENT FOR THE TIMING OF DELIVERY (TIME) AIM OF THE STUDY OF PREGNANCY AND NEONATAL HEALTH…Department of Health and Human Services$432.6K obligationsEnds Aug 31, 2024
NICHD: R&D: BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA) PEDIATRIC TRIALS NETWORK (PTN): CORE FUNCTION ACTIVITIES - THE CONTRACTOR SHALL ESTABLISH AND MAINTAIN CENTRALIZED TEAMS…Department of Health and Human Services$4.8M obligationsEnds Jun 3, 2027
HHSN275201800008I - NEW TASK ORDER PHASE 2: RECRUITMENT AND FOLLOW-UP STUDY OF PREGNANCY AND NEONATAL HEALTH (SPAN) (AIMS 1 AND 2) - DUKE UNIVERSITY - CAN 8050079Department of Health and Human Services$1.1M obligationsEnds May 31, 2027
PHARMACOKINETIC AND SAFETY OF ANTIRETROVIRAL AND RELATED DRUGS LACTATING WOMEN AND BREASTFED INFANTS STUDYDepartment of Health and Human Services$685.6K obligationsEnds Jun 30, 2026
BPCA INNOVATIVE TRIAL DESIGNS AND ASSAY DEVELOPMENTS IN PEDIATRIC THERAPEUTICSDepartment of Health and Human Services$8.8M obligationsEnds Sep 27, 2027
THE GOAL OF THIS TASK ORDER IS TO PERFORM PHARMACOEPIDEMIOLOGY RESEARCH AND A PK, PHARMACODYNAMIC, PHARMACOGENOMIC, EFFICIENCY, AND SAFETY TRIAL OF THE HIGHEST RECOMMENDED DOSE…Department of Health and Human Services$1.5M obligationsEnds Feb 14, 2027
"DEFINING THE SAFETY AND EFFICACY OF POSTERIOR TIBIAL NERVE STIMULATION IN CHILDREN(POSITRON-C)"Department of Health and Human Services$862.1K obligationsEnds Sep 5, 2025
IGF::OT::IGF PEDIATRIC TRIALSDepartment of Health and Human Services$3.7M obligationsEnds Sep 5, 2025
BPCA PHARMACOLOGY STUDIES - PERIOD OF PERFORMANCE: 9/14/18 - 9/13/22Department of Health and Human Services$9.8M obligationsEnds Mar 13, 2025
TO PROVIDE A PLATFORM FOR THE INCLUSION OF PATIENTS WITH DOWN SYNDROME INTO THE PHARMACOLOGY-BASED CLINICAL TRIALS. THE GOALS ARE TO RECRUIT THIS PATIENT POPULATION INTO THE…Department of Health and Human Services$6.8M obligationsEnds Jul 31, 2026
THE PURPOSE OF THIS TASK ORDER IS TO IDENTIFY THE REMAINING GAPS IN OFF-LABEL USE IN CHILDREN AND TO DESIGN CLINICAL RESEARCH (SYSTEMATIC LITERATURE REVIEWS, EPIDEMIOLOGY…Department of Health and Human Services$5.8M obligationsEnds Jul 12, 2027
BPCA PHARMACOEPIDEMIOLOGY (REAL WORLD DATA) STUDIESDepartment of Health and Human Services$2.4M obligationsEnds May 31, 2026
TO PERFORM INNOVATIVE TRIAL DESIGNS WITH CLINICALLY RELEVANT OUTCOMES SUCH AS ENDPOINTS, BIOMARKERS, AND EPIDEMIOLOGY DATA INCLUDED ASPART OF EVERY PROTOCOL, TO OBTAIN…Department of Health and Human Services$10.6M obligationsEnds Jul 31, 2025
PHARMACEUTICALS (PK) AND SAFETY OF COMMONLY USED DRUGS IN LACTATING WOMEN AND BREASTFED INFANTS (CUDDLE 2.0) NETWORKDepartment of Health and Human Services$4.0M obligationsEnds Jun 30, 2026
NICHD PEDIATRIC AND MATERNAL RESOURCE CENTER: BRIDGING PHARMACOLOGY AND THE REAL WORLDDepartment of Health and Human Services$6.3M obligationsEnds Sep 22, 2028
BPCA DATA CLOSEOUT DISSEMINATION AND ENGAGEMENTDepartment of Health and Human Services$4.4M obligationsEnds Sep 19, 2025
TASK ORDER 15: BPCA CONCEPT DEVELOPMENT, INVESTIGATOR DEVELOPMENT, AND CLINICAL TRIAL READINESS SUPPORTDepartment of Health and Human Services$2.1M obligationsEnds Sep 19, 2025
PHASE 2: RECRUITMENT AND FOLLOW-UP FOR THE TIMING OF DELIVERY (TIME) AIM OF THE STUDY OF PREGNANCY AND NEONATAL HEALTH (SPAN)Department of Health and Human Services$251.6K obligationsEnds Aug 31, 2025
2020.500-COVID-19 - BEST PHARMACEUTICALS FOR CHILDREN ACT PEDIATRIC TRIALS NETWORK - COVID-19 STUDIESDepartment of Health and Human Services$7.4M obligationsEnds Jul 31, 2025